9HPT (Dominant hand): Change from Part 1 baseline to each scheduled efficacy visit in Part 2
Subgroup Analysis: Confirmed Progression of disability
ITT population

Confirmed Progressors

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Change from Baseline to Week 156			
n	158	138	
Mean	10.12	5.01	0.1129
SD	33.675	20.625	

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for
    baseline EDSS (<=5.5 or >=6) and baseline 9HPT (dominant hand).

```
              9HPT (Dominant hand): Change from Part 1 baseline to each scheduled efficacy visit in Part 2
                            Subgroup Analysis: Confirmed Progression of disability
                                              ITT population

                                              Non Progressors
_____

                                             Placebo to              Natalizumab
                                         Natalizumab 300 mg             300 mg                 p-value (a)
_____

Change from Baseline to Week 156
  n                                            99                        133
  Mean                                        -2.60                     -0.89                    0.2351
  SD                                           9.543                    10.602




_____
(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for
    baseline EDSS (<=5.5 or >=6) and baseline 9HPT (dominant hand).
```